iBio, Inc.IBIONYSE
Loading
Free Cash Flow Growth Under PressureDecelerating
Percentile Rank79
5Y CAGR+42.6%
Studio
Year-over-Year Change

Year-over-year free cash flow growth rate

5Y CAGR
+42.6%/yr
Long-term compound
Percentile
P79
Within normal range
vs 5Y Ago
5.9x
Strong expansion
Streak
1 yr
Consecutive declineDecelerating
PeriodValue
202518.35%
202448.13%
202319.85%
2022-28.12%
2021-142.95%
20203.11%
2019-2.79%
20181.34%
2017-81.28%
2016-64.78%